Eisai Co. vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eisai Co., Ltd. (4523.JP)

Q3 202630 Jun – 25 Sep 2026

▲4

Eisai Q3: Leqembi at-home approvals and oncology wins drive growth

Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.
This is a major new approval and launch that directly impacts Eisai's growth prospects.
Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.
Sales and royalty figures are key financial metrics showing Leqembi's market performance.
Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.
New approvals and validations in oncology represent additional growth drivers beyond Leqembi.
AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.
This strategic move may improve long-term R&D efficiency and is a new development.

August 202629 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

Latest29 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

July 202630 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

30 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

Regeneron Pharmaceuticals Inc (REGN)

Q3 20264 Jul – 1 Oct 2026

▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.
Strong financial results directly boost investor confidence and the stock price.
Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.
This major setback significantly impacted Regeneron's market value and reputation.
Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.
The deal has both positive financial aspects and negative implications for Dupixent economics.

September 202617 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest17 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 202627 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

27 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

July 20264 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

4 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

19 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.